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Outcomes of hepatitis C virus (HCV) infection and treatment depend on viral and 51	
host genetic factors. We use human genome-wide genotyping arrays and new 52	
whole-genome HCV viral sequencing technologies to perform a systematic genome-53	
to-genome study of 542 individuals chronically infected with HCV, predominately 54	
genotype 3. We show that both HLA alleles and interferon lambda innate immune 55	
system genes drive viral genome polymorphism, and that IFNL4 genotypes 56	
determine HCV viral load through a mechanism that is dependent on a specific 57	
polymorphism in the HCV polyprotein. We highlight the interplay between innate 58	
immune responses and the viral genome in HCV control.  59	
Introduction 60	
 61	
Hepatitis C virus (HCV) infection presents a major health burden, infecting more than 62	
185 million people worldwide1 and leading to liver failure and hepatocellular cancer. 63	
Both host and virus genetic variations are associated with important clinical 64	
outcomes. Host genetic polymorphisms, most notably in the interferon lambda 3 and 65	
4 locus, are associated with spontaneous clearance of the virus, response to 66	
treatment, viral load and progression of liver disease2–6. Viral genotypes and distinct 67	
viral genetic motifs have been associated with the response to interferon based 68	
therapies7,8 whilst resistance-associated substitutions (RASs) have been identified 69	
for most of the new oral direct-acting antiviral (DAA) drugs9–12. HCV can be divided 70	
into seven major genotypes, and most of the genetic data acquired to date focuses 71	
on HCV genotype 1 with a lack of data addressing other genotypes. HCV genotype 3 72	
is of particular interest as this genotype is known to infect 53 million people globally13 73	
and is associated with a higher failure rate to DAA therapies14,15. 74	
 75	
Previous work has shown that within-host virus diversity evolves in response to the 76	
adaptive immune system, including candidate genes studies of the association 77	
between the human leukocyte antigen (HLA) type I proteins with the HCV 78	
genome16,17. HLA molecules are expressed on most cell types and present viral 79	
peptides (epitopes) to cytotoxic T lymphocytes (CTLs) that kill infected cells. CTL-80	
mediated killing of virus-infected cells drives the selection of viral polymorphisms 81	
(“escape” mutants) that abrogate T cell recognition18. Understanding how host HLA 82	
molecules impact on viral selection has important implications for the development of 83	
HCV T-cell vaccines that aim to prevent infection19,20. A comprehensive host genome 84	
	 4	
to viral genome analysis at scale will assess the relative contribution of host HLA 85	
molecules in driving HCV genetic change and this analysis may also reveal other 86	
host genes that play a key role in shaping the HCV genome.  87	
 88	
We generated data from a cohort of 601 HCV infected patients (from the BOSON21 89	
clinical trial) to systematically look for associations between host and virus genomes, 90	
exploiting the fact that while host genetics remain fixed, the virus mutates, allowing it 91	
to evolve during infection. For this we developed targeted viral enrichment22,23 to 92	
obtain whole HCV genomes, and used high-throughput genotyping arrays in 93	
combination with statistical imputation to obtain data on HLA alleles24,25 and 94	
nucleotide polymorphisms across the human genome. We provide evidence that 95	
polymorphisms relevant to the innate (IFNL4) and adaptive immune systems (HLA 96	
genes) are associated with HCV sequence polymorphisms. We show that an 97	
interaction between host IFNL4 genotypes and a viral site in the NS5A protein 98	
determines HCV viral load. By assessing viral evolution in individuals with different 99	
IFNL4 genotypes, we highlight systematic differences in the innate immune response 100	
and discuss how these might relate to previous associations with spontaneous 101	
clearance and clinical treatment. We demonstrate the potential for a joint analysis of 102	
host and viral genomic data to provide information on underlying molecular 103	
interactions and their importance in treating and preventing HCV, and other viral 104	
infections, in the era of genomic analysis.  105	
Results 106	
Sample description and genetic structure 107	
 108	
DNA samples from 567 patients (out of 601 patients) were genotyped using the 109	
Affymetrix UK Biobank array. This array genotypes over 800,000 single nucleotide 110	
polymorphisms (SNPs) across the human genome, including a set of markers 111	
specifically chosen to capture common HLA alleles. Pre-treatment plasma samples 112	
from 583 patients in the same study were analysed to obtain HCV whole genome 113	
consensus sequences using a high-throughput HCV targeted sequence capture 114	
approach coupled with Illumina sequencing22.  115	
 116	
Both full-length HCV genome sequences and human genome-wide SNP data were 117	
obtained on a total of 542 patients of mainly White and Asian self-reported ancestry 118	
infected with HCV genotypes 2 or 3 (Supplementary Table 1). After quality control 119	
	 5	
and filtering of the human genotype data, approximately 330,000 common SNPs with 120	
minor allele frequency greater than 5% were available for analysis along with inferred 121	
alleles at both class I and II HLA genes. The full-length HCV genome is 122	
approximately 9.5 kb, corresponding to over 3000 encoded amino acids. In our 123	
dataset, 1226 sites of the HCV proteome were defined to be variable (where at least 124	
10 isolates have an amino acid which differs from the consensus amino acid) to have 125	
minimal statistical power for analysis.  126	
 127	
We characterised human genetic diversity in the cohort via principal component 128	
analysis (PCA). The first two principal components (PCs) corresponded to the 129	
sample’s 83% White and 14% Asian self-reported ethnicity, (Supplementary Figure 130	
1), which differed significantly in some of the inferred HLA alleles frequencies 131	
(Supplementary Table 2) consistent with previous observations26. The third PC 132	
separates individuals with Black self-reported ethnicity from the rest of the cohort.  133	
We summarised virus diversity by constructing a maximum-likelihood tree of the 134	
consensus sequences from each patient (Supplementary Figure 2). Major clades in 135	
the tree separated HCV genotypes 2 (8% of the sample) and 3 (which in turn 136	
comprised clades representing subtype 3a and non-subtype 3a samples (90% and 137	
2% of the total respectively)). We observed that patients of specific ancestries, 138	
measured either by genetic ancestry (PCs), or self-reported ethnicity, clustered 139	
together on the tree of viral diversity (Supplementary Figure 2). A PCA on virus 140	
nucleotides sequence data reflected the structure of the tree, specifically at the level 141	
of virus subtypes (Supplementary Figure 3).  142	
 143	
Systematic host genome to virus genome analysis 144	
 145	
We used the genotyped autosomal SNPs in the host genome to undertake genome-146	
wide association studies, where the traits of interest were the presence or absence of 147	
each amino acid at the variable sites of the virus proteome, resulting in nearly one 148	
billion association tests. We performed logistic regression assuming an additive 149	
model, and adjusting for sex, and population structure by including the first three PCs 150	
of the host and the first ten PCs of the virus as covariates. Failure to control for either 151	
covariates leads to a significant inflation in the association test statistics 152	
(Supplementary Figure 4), as would be expected given the observed correlation in 153	
population structure of the virus and the host (Supplementary Figure 2). Assuming 154	
a human genome-wide significance threshold27 of 5x10-8,  and that amino acid 155	
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variants in the viral genome are approximately uncorrelated once the population 156	
structure is accounted for, then a Bonferroni correction28 results in a significance 157	
threshold of approximately 2x10-11. 158	
 159	
160	
  Figure 1. Human to hepatitis C virus genome-wide association study in 542 161	
patients. The lower arc shows the human autosomes from chromosome 1 to 22, and 162	
the upper arc shows the HCV proteome from core (C) to NS5B. The red line 163	
represents the most significant association, P<2x10-11. The four blue lines represent 164	
suggestive associations, P<4x10-9. The thin grey lines represent associations with 165	
P<10-5. The outer mini-panels represent, on the upper arc, the viral diversity as 166	
measured by Shannon entropy and, on the lower arc, the density of human SNPs in 167	





Across the human genome, the most significant associations were observed 172	
between multiple SNPs in the major histocompatibility complex (MHC; chromosome 173	
6) locus and a virus amino acid variant in non-structural protein 3 (NS3) (Figure 1). 174	
Three other associations were observed between multiple SNPs in the host MHC 175	
and virus amino acids in NS3 and NS4B proteins (P<4x10-9, Figure 1). Outside the 176	
MHC, the strongest association between host and virus was detected between the 177	
SNP rs12979860 in the IFNL4 gene (chromosome 19) and HCV amino acids at 178	
position 2570 in NS5B protein (P=1.98x10-9, Figure 1). Observed variability in the 179	
density of nominally significant associations (Figure 1) is largely explained by 180	
variability in host and virus sequences, for example in the hyper-variable region 181	
(HVR) of HCV in E2 protein. 182	
 183	
We observed 182 associations between human SNPs mapping to two loci and five 184	
HCV amino acid sites (P<4x10-9) (Supplementary Table 3). Since these 185	
associations represent places where host genetic diversity has impacted on virus 186	
sequence diversity we refer to them as “footprints”. We interpret the signals of 187	
association in the MHC region to indicate the effect of the adaptive immune system 188	
on genetic diversity in the virus genome. Whilst the effect of MHC was anticipated, 189	
the strong signal of association of the interferon lambda region with viral diversity 190	
indicates additional effects of the innate immune response. 191	
Host HLA alleles to virus genome 192	
 193	
SNPs in the MHC which show strong association with viral amino acids are likely to 194	
be correlated with alleles at HLA genes due to extensive linkage disequilibrium 195	
across the region29,30.  The HLA repertoire of a patient defines which viral peptides 196	
will be presented to T-cells as part of the adaptive immune response, and can lead to 197	
the selection of viral mutations (“escape mutations”)16,31–34. Upon transmission to 198	
another host, with a different HLA repertoire, reversion to the wild type may occur 199	
(“reversion mutations”). To test for footprinting of the host HLA alleles along the viral 200	
genome (Figure 2a and Table 1), we inferred the changes on the terminal branches 201	
of the virus phylogenetic tree for each amino acid site and assessed association with 202	
the hosts’ HLA alleles. We repeated the analysis on patients infected with genotype 203	
3a and self-reporting as White (Table 1 and Supplementary Figure 5).  204	
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 205	
Figure 2. Hepatitis C virus genome-wide association studies. Association 206	
between HCV amino acids and (a) HLA alleles (Fisher’s exact test) (b) IFNL4 207	
genotypes (Fisher’s exact test) and (c) pre-treatment viral load (log10PTVL, linear 208	
regression). Sites in experimentally validated epitopes in HCV genotype 3 are 209	
indicated by a plus sign. Viral sites 1444, 2414 and 2570 are coloured as red. 210	
Dashed lines represent a 5% false discovery rate. (d) HCV polyprotein.   211	
 212	
 213	
In the whole cohort, at a 5% FDR, 24 combinations of HLA alleles and HCV sites 214	
were significant (Table 1) and this increased to 153 associations at a 20% FDR 215	
(Supplementary Table 4). Out of 21 viral amino acid positions showing signals of 216	
association with one or more HLA alleles, 12 were located in previously reported 217	
HCV genotype 3 epitopes20 (Table 1), which represents a strong enrichment (odds 218	
ratio, OR=5.2, P=2.8x10-4). We also observed that NS3 protein was strongly enriched 219	
for association signals with HLA alleles (OR=5.5, P=2.2x10-4). The strongest HLA 220	
footprints are found with common alleles at HLA-A and HLA-B genes, although 221	
signals are also found in HLA-C and the class II gene HLA-DQA1. (See 222	
Supplementary notes and Supplementary Figures 6, 7 and 8 for detailed 223	
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description of the most significant association between HLA-A and Y1444F). At 224	
position 1646 in the HCV genome (in NS3), the footprint is seen with multiple HLA 225	
alleles (B*08:01, C*07:01 and DQA1*05:01), although this is potentially a result of 226	
linkage disequilibrium between these HLA alleles (r2 between B*08:01 and C*07:01 = 227	
0.49, and r2 between B*08:01 and DQA1*05:01 = 0.22; Supplementary Figure 9). 228	
Using the 27 HLA and viral amino acid associations at a 20% FDR that have 229	
sufficient observations to estimate the ORs, we observed a negative correlation 230	
between the ORs of escape and reversion (r=-0.65, P<0.01; Supplementary Figure 231	
10). These observations are consistent with HLA alleles driving patterns of both 232	
escape and reversion at viral amino acids. Our analysis provides a map of their 233	
influence across the HCV genome.  234	
 235	
IFNL4 host variants to virus genome  236	
 237	
Variants in the interferon lambda region have been associated with multiple HCV 238	
outcomes including spontaneous clearance, treatment response, viral load and liver 239	
disease progression2,3,35. In our genome-wide analysis, variants around the interferon 240	
lambda region showed the strongest association with HCV amino acids outside the 241	
MHC region (the top associated SNP is rs12979860, P=1.98x10-9). For SNP 242	
rs12979860, the CC genotype is associated with higher rates of spontaneous 243	
clearance and interferon-based treatment response, putatively due to the fact that 244	
the C allele tags a dinucleotide insertion polymorphism (rs368234815-TT) which 245	
prevents IFNL4 expression36. In our cohort, only two individuals had discordant 246	
genotypes for rs12979860 and rs368234815 (which was imputed), resulting in a 247	
strong linkage disequilibrium (r2=0.99) between these two SNPs. Therefore, 248	
individuals with non-CC genotypes express IFNL4 and have increased expression of 249	
hepatic interferon stimulated genes (ISGs)37.  250	
 251	
We compared viral amino acid changes between hosts with CC and non-CC 252	
genotypes at the IFNL4 SNP rs12979860 using the same Fisher’s exact test as 253	
described above. The most significant association was with changes to and away 254	
from valine (V) at position 2570 in the viral NS5B protein (P=1.94x10-11, Figure 2b). 255	
We replicated this association in an independent study of 360 patients of European 256	
ancestry chronically infected with HCV genotypes 2 or 338,39 (one-sided P=0.005). In 257	
addition, a candidate gene association study in a genotype 1b single source infection 258	
cohort has shown an association between IFNL4 genotypes (rs12979860) and an 259	
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amino acid in the same region of NS5B (position 2609)32 reinforcing the potential role 260	
of the locus in interactions with the host innate immune system. 261	
 262	
Overall, using a 5% FDR, 11 significant associations were observed between IFNL4 263	
genotypes and amino acid positions located in core, E2, NS5A and NS5B proteins 264	
(Supplementary Table 5). Using a permutation approach, we found that the core 265	
protein is nominally (P<0.05) enriched, and the NS5A protein is nominally depleted, 266	
in the number of associations with the IFNL4 genotypes. Genotype 3a viral 267	
sequences in individuals with the CC genotype did have more mutations away from 268	
the population consensus than non-CC individuals (See Supplementary Note and 269	
Supplementary Table 6).  One of the sites (position 109 in the core protein) is also 270	
associated with HLA-B*41:02 (P=4.3x10-6, Table 1). However, we did not find any 271	
consistent evidence for interaction between by HLA alleles and IFNL4 genotypes and 272	
their association with viral amino acids (Supplementary Figure 11). Nor did we find 273	
strong differences in the mean number of escape mutations in CC and non-CC 274	
patients when comparing HLA allele carriers and non-HLA allele carriers.  275	
 276	
To further investigate the selective pressures on the virus in patients with IFNL4 CC 277	
and non-CC genotypes, we estimated the rates of synonymous (dS) and non-278	
synonymous substitutions (dN) in genotype 3a infected patients (Figure 3). Whilst 279	
there was no difference in dS in CC and non-CC patients (P=0.68, Figure 3a), dN 280	
was significantly higher in CC patients (P=1.6 x10-8, Figure 3b). The lower dN/dS 281	
ratio in non-CC patients (P=1.3x10-10) is potentially indicative that the virus is under a 282	
stronger purifying selection (Figure 3c). This hypothesis is supported by the 283	
observation that for the same rate of synonymous substitutions dS (a surrogate for 284	
the time and amount of divergence), the HCV genome is under a larger purifying 285	




Figure 3. Association between IFNL4 genotypes and substitution rates in 289	
genotype 3a infected patients. Stratification of substitution rates by IFNL4 CC and 290	
non-CC genotypes. (a) Rate of synonymous substitutions (dS, P=0.68), (b) Rate of 291	
non-synonymous substitutions (dN, P=1.6x10-8) and (c) dN/dS ratio (P=1.28x10-10). 292	
Each blue dot represents the mean dS, dN or dN/dS ratio per patient. The mean and 293	
95% confidence intervals are shown as black dots and bars. (d) The joint distribution 294	
of dS and dN/dS in individuals with the IFNL4 non-CC genotypes (red dots) and with 295	
the CC genotype (blue dots). 296	
 297	
 298	
Estimating dN/dS ratio per viral gene showed that this ratio was significantly higher 299	
(P<0.05) in CC patients compared to non-CC patients in E1, E2, NS3 and NS5B 300	
(Supplementary Figure 12). A sliding window analysis across the HCV genome 301	
showed that in the full cohort E1 and E2 genes had a much higher dN/dS ratio 302	
compared to the rest of the genome. These envelope genes include hyper-variable 303	
regions (HVRs), and are thought to be the primary targets of the antibody-based 304	
immune response (Supplementary Figure 13).  305	
 306	
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Host and virus genetic determinants of viral load 307	
 308	
We performed a genome-wide association study in patients infected with HCV 309	
genotype 3a using an additive linear regression model adjusted for sex and the three 310	
first host PCs for log10 transformed of pre-treatment viral load (log10PTVL) (Figure 311	
4a). We replicated the known association between IFNL4 variants on chromosome 312	
19 and viral load3 (rs12979860, P=5.9x10-10) with the non-CC genotypes conferring 313	
an approximately 0.45-fold decrease in viral load (mean for non-CC=3.4760x106 314	
IU/mL and for CC=6.3447x106 IU/mL). We also performed a genome-wide 315	
association study to detect associations between viral amino acids of genotype 3a 316	
virus and viral load (Figure 2c). The only amino acid significantly associated with 317	
log10PTVL at a 5% FDR was a change from a serine (S) to an asparagine (N) at 318	
position 2414 in NS5A protein (P=9.21x10-7, Figure 4b). This site is one of the 11 319	
sites significantly associated (5% FDR) with IFNL4 genotypes (Figures 2b and 2c).  320	
 321	
Figure 4. Association between viral load and human and virus genetic variants 322	
in genotype 3a infected patients. (a) Association between human SNPs and 323	
log10PTVL, (b) Distribution (blue dots), estimated mean and 95% confidence interval 324	
(shown as black dots and bars) of log10PTVL stratified by amino acids present at viral 325	
position 2414 (P=9.21x10-7), (c) by IFNL4 (CC, CT and TT) genotypes in patients 326	
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whose virus carries a serine at position 2414 (P=9.37x10-9) or (d) in patients whose 327	
virus does not carry a serine amino acid at position 2414 (P=0.9).  328	
 329	
 330	
In patients with a serine at position 2414, the association between IFNL4 genotypes 331	
and log10PTVL is significant (P=9.37x10-9, Figure 4c). However, we observed no 332	
association (P=0.9) between IFNL4 genotypes and log10PTVL in patients infected 333	
with a virus that has a different amino acid  (Figure 4d). In other words, the host’s 334	
IFNL4 genotypes determine viral load only if they are infected by a virus with the 335	
serine amino acid at position 2414 in NS5A protein (Figures 4c and 4d). The 336	
interaction is statistically significant when analysing either the whole cohort (P=0.017) 337	
or just patients with genotype 3a infections who self-report as being White (P=0.017). 338	
Together the combinations of non-CC genotypes and a serine viral amino acid at 339	
position 2414 are inferred to result in a 0.57-fold decrease in viral load compared to 340	
all other combinations (mean viral load for non-CC and serine at position 2414 341	
=2.81x106 IU/mL and all other combinations =6.47x106 IU/mL). Introduction of the 342	
change from a serine to an asparagine at position 2414 into a modified S52 replicon 343	
of genotype 3a40 resulted in a approximately 10-fold increase in replication in Huh7.5 344	
cell culture (Supplementary Note and Supplementary Figure 14). 345	
 346	
We also observed that non-consensus amino acids, which are increased in 347	
frequency in individuals with a CC genotype, tend to also associate with increased 348	
viral load (r=0.42, P=0.005, Supplementary Figure 15). The same positive 349	
relationship was observed when estimating the effect on viral load in individuals with 350	
a CC genotype only (r=0.35, P=0.02) or non-CC genotypes only (r=0.4 and 351	
P=0.007). A nominally significant trend was observed when the analysis was done 352	
for all variant positions in the viral genome (r=0.099 and P=0.04) (Supplementary 353	
Figure 16).  354	
Discussion 355	
 356	
Here we report the first systematic analysis of associations between variation in 357	
human and HCV genomes in a large patient cohort. Advances in DNA and RNA 358	
sequencing technology and new bioinformatics tools have allowed full-length viral 359	
consensus sequences to be obtained in large number of patients for reasonable cost 360	
(approximately £100 per sample), as well as host genetic data at millions of directly 361	
assayed and imputed polymorphisms (approximately £75 per sample). We apply a 362	
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fast and simple approach to test for association between host and pathogen variants, 363	
using a logistic regression analysis corrected for both human and viral population 364	
structures by using the principal components of the genome-wide data as covariates 365	
(60 hours for approximately 2500 association studies of 330,000 SNPs). We also 366	
applied a contingency table analysis based on the inferred viral amino acid changes 367	
since infection. We anticipate that with the reduction in the cost of sequencing and 368	
genotyping, and the increasing interest in studying large patient cohorts, analyses of 369	
this kind will become a powerful approach to understanding infectious diseases. 370	
Confirmation of the specific associations reported here, and the extent to which they 371	
are specific to viral genotype, will require replication analysis in independent cohorts.  372	
 373	
We found strong evidence for the adaptive immune system exerting selective 374	
pressures on the HCV genome, presumably by preferentially selecting viral 375	
mutations that avoid antigenic presentation by the host’s HLA proteins. Some of the 376	
observed associations are located in experimentally validated viral epitopes20, 377	
however others have not been described experimentally and most likely represent 378	
sites of novel T-cell escape mutations. Assuming that our analysis removes biases 379	
associated with population structure and incorrect ancestral inference, 5% of the viral 380	
amino acids (153/3021) are associated with HLA alleles (at 20% FDR). These data 381	
highlight the importance of the adaptive immune system in driving viral evolution, and 382	
serves as a map of the targets of T-cell based immunity along the HCV genome 383	
which can aid vaccine design and development20.  384	
 385	
In addition to the HLA, we now show that IFNL4 activity may significantly shape the 386	
HCV viral genome. Previous studies have shown that the “favourable” CC IFNL4 387	
genotype increases the chances of spontaneous resolution and interferon-based 388	
treatment success2–6. The IFNL4 TT/TT genotype (rs368234815), which is strongly 389	
linked to the “favourable” CC genotype (rs12979860), abolishes the expression of 390	
IFNL446, whereas in individuals with the IFNL4 ΔG/TT or ΔG/ΔG genotypes (linked 391	
to “ unfavourable” non-CC genotypes), IFNL4 is expressed, leading to the 392	
downstream up-regulation of hepatic ISGs expression via the JAK-STAT pathway37. 393	
The expression of ISGs has been shown to render the host less susceptible to 394	
exogenous IFNα/γ stimulation and is associated with more infected cells in the 395	
liver42. To date it has been presumed that this fully explains why patients with specific 396	




Our analysis adds to this hypothesis, with the observation that IFNL4 variants also 400	
impact on the HCV genome at multiple amino acid sites. Indeed, these were the 401	
strongest footprinting signals in our systematic analysis outside HLA region. The 402	
most significant association was at position 2570 in the viral NS5B protein; an 403	
association that we replicated in an independent cohort infected with HCV genotypes 404	
2 and 3. The additional signals in NS5B protein associated with HLA alleles or IFNL4 405	
genotypes at a 5% FDR did not replicate (P > 0.05) potentially due to a lack of power 406	
resulting from the smaller sample size of the replication cohort and/or the fact that 407	
the phylogenetically corrected Fisher’s tests could not be performed in an equivalent 408	
way. An association between IFNL4 and amino-acid variability in the same region of 409	
NS5B protein, has previously been reported in a candidate gene study32 in a single 410	
source infection cohort. IFNL4 has also been associated with a viral mutation 411	
associated with DAA resistance in HCV genotype 1 infection44 although this 412	
association has not been replicated in our HCV genotype 3 cohort45. The additional 413	
signals in NS5B protein associated with IFNL4 genotypes (or HLA alleles) at a 5% 414	
FDR did not replicate (P > 0.05) potentially due to a lack of power resulting from the 415	
smaller sample size of the replication cohort and/or the fact that the phylogenetically 416	
corrected Fisher’s exact tests could not be performed in an equivalent way (only 417	
NS5B sequences were available in the replication cohort). However, the broader 418	
impact of interferon lambda host genes that are associated with, and potentially 419	
select for, specific viral variants has not been previously recognised. 420	
 421	
HCV viral load is an important and clinically relevant parameter since patients with 422	
higher HCV viral loads have lower response rates to IFN and DAA based therapy46 423	
(independent of IFNL4 status). Paradoxically, the “favourable” IFNL4 variants have 424	
also been associated with both an increase in disease progression47 and high viral 425	
load3,48. We report an association between a virus amino acid site (serine vs. non-426	
serine at position 2414 in NS5A) and HCV viral load. This site is one of the 11 sites 427	
that are putatively associated with IFNL4 genotypes in our dataset. Further, our data 428	
shows that a decrease in viral load was only observed in those patients with non-CC 429	
genotypes whose virus carried the serine amino acid at site 2414 in NS5A protein. 430	
Since the 2414 S variant is found in 85% of non-CC patients (compared to 67% of 431	
CC patients), this interplay between host and viral genes helps explain the previous 432	
observation that non-CC patients have a lower HCV viral load (Figure 5). Our in vitro 433	
data from a genotype 3 replicon assay shows that a change from a serine to 434	
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asparagine at site 2414 is associated with an increase in RNA replication and 435	
perhaps hyper-phosphorylation49, which is a negative regulator of virus replication.  436	
 437	
Figure 5: Overview of the observations relating to the interplay between innate 438	
immune response and the viral genome in hepatitis C virus control. (a) Infected 439	
individuals with IFNL4 CC genotype (37% of the HCV genotype 3a infected patients) 440	
show high rates of spontaneous and treatment-induced clearance of HCV. IFNL4 is 441	
not expressed, which in turn induces a weaker and possibly differential interferon-442	
stimulated genes (ISG) expression. The host environment is associated with weaker 443	
purifying selection and allows viral mutations associated with a better replicative 444	
fitness to accumulate, leading to higher viral load. In this group of patients, 67% are 445	
infected by a virus with a serine at position 2414 and 33% with a different amino-446	
acid. (b) Infected individuals with IFNL4 non-CC genotypes (63% of the HCV 447	
genotype 3a infected patients), have lower rates of spontaneous and treatment-448	
induced clearance of HCV. IFNL4 is expressed and induces ISGs that collectively 449	
establish an antiviral state hostile to viral replication. This hostile environment 450	
induces a high selective pressure and fewer viral mutations can accumulate. 451	
Although the serine at position 2414 (compared to non serine) is associated with 452	
lower viral load, it is highly prevalent in this group of patients (85% are infected by a 453	
virus with a serine at position 2414 and 15% with a different amino-acid). 454	
 455	
Our interpretation of the data (Figure 5) is that the expression of IFNL4 by ΔG/TT or 456	
ΔG/ΔG genotypes (tagged in our cohort by the “unfavourable” non-CC genotypes) 457	
leads to the activation of additional components of the immune response, likely 458	
driven by ISGs, which interact directly with specific amino acids in the viral genome 459	
(most notably amino acid 2414 in NS5A which has a significant impact on viral load 460	
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(Figures 2b, 4 and Supplementary Figure 15). Our data suggest that this also 461	
leads to an overall increase in the strength of purifying selection (decrease in dN/dS, 462	
Figure 3), and together this leads to lower viral load. However, viruses that establish 463	
chronic infections in non-CC patients have evolved to survive in a more hostile 464	
environment (for example mutating the serine at amino acid 2414 of NS5A), which 465	
makes them less likely to respond to interferon-based therapy. In contrast, our 466	
analysis suggests that the “favourable” CC genotype and the inactivation of IFNL4 467	
gene (by the IFNL4 TT genotype) disables components of the immune response 468	
(therefore removing the effect of amino acid 2414 in NS5A on viral load), which leads 469	
to a reduced level of purifying selection (Figure 3). It is possible that this then 470	
permits a range of mutations which confer higher replicative fitness and therefore 471	
higher viral load (Supplementary Figure 15), but these viruses are more susceptible 472	
to interferon-based treatments.  At the population level, we would expect a balance in 473	
the relative contribution of these mechanisms as viruses move between individuals 474	
with CC and non-CC genotypes. Our results make the prediction that the outcome of 475	
a new infection will be dependent on both the HLA alleles and the IFNL4 genotype of 476	
the patient who is the source of the new infection. Further analysis is required to fully 477	
understand the impact of “favourable” CC and “unfavourable” non-CC genotypes on 478	
the different components of the immune system and to establish their clinical 479	
relevance before, during and after infection. 480	
 481	
In conclusion, we provide a comprehensive genome-to-genome analysis in chronic 482	
HCV infection. Using this genome-wide, hypothesis-free, approach we show that the 483	
host’s HLA alleles leave multiple footprints in the HCV genome and that the host’s 484	
innate immune environment also influences the amino acid polymorphisms in the 485	
virus, both at specific loci, and genome-wide. We observe a common viral amino-486	
acid residue that is associated with HCV viral load only in patients with the 487	
“unfavourable” non-CC IFNL4 genotypes. These observations suggest that the 488	
innate and adaptive immune system jointly impact on HCV genome evolution and 489	
likely together determine the establishment of infection and its control over time. The 490	
new insights into the biological mechanisms that drive HCV evolution in vivo, and the 491	
identification of specific interactions between viral and host polymorphisms are 492	
relevant for future approaches to treatment stratification and vaccine development. 493	
  494	
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Online Methods  555	
Patients and sample 556	
Plasma and DNA samples came from patients enrolled in the Boson study. Boson 557	
study is a phase 3 randomized open-label trial to determine the efficacy and safety of 558	
sofosbuvir with and without pegylated-interferon-alfa, in treatment-experienced 559	
patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and 560	
treatment-naïve or -experienced patients with HCV genotype 3 infection21. All 561	
patients provided written informed consent before undertaking any study-related 562	
procedures. The study protocol was approved by each institution’s review board or 563	
ethics committee before study initiation. The study was conducted in accordance with 564	
the International Conference on Harmonization Good Clinical Practice Guidelines 565	
and the Declaration of Helsinki. The study reported here is not a clinical trial, but is 566	
based on the analysis of patients from a clinical trial (registration number: 567	
NCT01962441).  Sample sizes were determined by the available data. All samples 568	
for which both viral sequencing and host genetics were available were included in the 569	
final analysis unless otherwise specified. 570	
Host genotyping and imputation 571	
Informed consent for host genetic analysis was obtained from 567 patients. 572	
Genotyping was performed using Affymetrix UK Biobank arrays. We imputed the 573	
MHC class I loci HLA-A, HLA-B, HLA-C and class II loci HLA-DQA1, HLA-DQB1, 574	
HLA-DPB1, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5 using HLA*IMP:0224 575	
accessed 22 March 2015.  HLA amino acids were also imputed by SNP2HLA50 using 576	
the T1DGC as the reference panel, which contains 5225 unrelated individuals 577	
(10,450 haplotypes). Logistic regression using posterior genotype probabilities (allele 578	
dosages) for each HLA allele from SNP2HLA were carried out using PLINK251 579	
(https://www.cog-genomics.org/plink2). 580	
Virus sequencing 581	
Sample collection and preparation 582	
RNA was isolated from 500µl plasma using the NucliSENS magnetic extraction 583	
system (bioMerieux) and collected in 30µl of kit elution buffer for storage in aliquots 584	
at -80°C. 585	
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Sequencing library construction, enrichment and sequencing 586	
Libraries were prepared for Illumina sequencing using the NEBNext® Ultra™ 587	
Directional RNA Library Prep Kit for Illumina® (New England Biolabs) with 5µl 588	
sample (maximum 10ng total RNA) and previously published modifications of the 589	
manufacturer’s guidelines (v2.0)22, briefly: fragmentation for 5 minutes at 94°C, 590	
omission of Actinomycin D at first-strand reverse transcription, library amplification 591	
for 18 PCR cycles using custom indexed primers52 and post-PCR clean-up with 592	
0.85× volume Ampure XP (Beckman Coulter). 593	
 594	
Libraries were quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen) 595	
and analysed using Agilent TapeStation with D1K High Sensitivity kit (Agilent) for 596	
equimolar pooling, then re-normalized by qPCR using the KAPA SYBR® FAST 597	
qPCR Kit (Kapa Biosystems) for sequencing.  A 500ng aliquot of the pooled library 598	
was enriched using the xGen® Lockdown® protocol from IDT (Rapid Protocol for 599	
DNA Probe Hybridization and Target Capture Using an Illumina TruSeq® or Ion 600	
Torrent® Library (v1.0), Integrated DNA Technologies) with equimolar-pooled 120nt 601	
DNA oligonucleotide probes (IDT) followed by a 12-cycle, modified, on-bead, post-602	
enrichment PCR re-amplification. The cleaned post-enrichment ve-Seq library was 603	
normalized with the aid of qPCR and sequenced with 151b paired-end reads on a 604	
single run of the Illumina MiSeq using v2 chemistry. 605	
Sequence data analysis 606	
De-multiplexed sequence read-pairs were trimmed of low-quality bases using 607	
QUASR v7.012053 and adapter sequences with CutAdapt version 1.7.154 and 608	
subsequently discarded if either read had less than 50b remaining sequence or if 609	
both reads matched the human reference sequence using Bowtie version 2.2.455. 610	
The remaining read pool was screened against a BLASTn database containing 165 611	
HCV genomes56 covering its diversity both to choose an appropriate reference and to 612	
select those reads which formed a majority population for de novo assembly with 613	
Vicuna v1.357 and finishing with V-FAT v1.0 (http://www.broadinstitute.org/scientific-614	
community/science/projects/viral-genomics/v-fat). Population consensus sequence at 615	
each site is defined as the most common variant at that site among all the patients. 616	
Phylogenetic and ancestral sequence reconstruction 617	
Whole genome viral consensus sequences for each patient were aligned using 618	
MAFFT58 with default settings. This alignment was used to create a maximum 619	
likelihood tree using RAxML59, assuming a general time reversible model of 620	
nucleotide substitution under the gamma model of rate heterogeneity. The resulting 621	
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tree was rooted at midpoint. Maximum likelihood ancestral sequence reconstruction 622	
was performed using RAxML59 with the maximum likelihood tree and HCV 623	
polyprotein sequences as input.  624	
Association analysis 625	
To test for association between human SNPs and HCV amino acids at genome-to-626	
genome level, we performed logistic regression using PLINK251 (https://www.cog-627	
genomics.org/plink2) adjusted for the human population structure (three first PCs 628	
assessed using EIGENSOFT v3.060) and the virus population structure (10 first PCs). 629	
For the viral data PCA was performed on the nucleotide data. Tri and quad-allelic 630	
sites were converted to binary variables and the amino acid frequencies were 631	
standardised to have mean zero and unit variance. MATLAB (Release 2015a, The 632	
MathWorks) was used to perform the PCA using the singular value decomposition 633	
function.  634	
 635	
To test for association between imputed HLA alleles and HCV amino acids, we used 636	
Fisher’s exact test, correcting for the virus population structure as described in 637	
Bhatacharaya et al.61. We used the inferred ancestral amino acid to estimate 638	
changes for each site on the terminal branches of the virus phylogenetic tree. 639	
Inferring the changes along the terminal branches of the tree aims to control for the 640	
confounding between host and virus population structures61 by looking at viral 641	
mutations after infection. We construct a 2x4 contingency table where rows denote 642	
presence or absence of a host HLA allele, and the columns denote changes to and 643	
away from a specific amino acid in viruses with and without the amino acid inferred to 644	
be ancestral. To test for association between IFNL4 SNP rs12979860 genotypes and 645	
HCV amino acids, we used the same Fisher’s exact test with a dominant model for 646	
IFNL4 rs12979860 by encoding genotypes as CC and non-CC. 647	
 648	
Permutation was used to estimate the FDR for association tests that used Fisher’s 649	
exact test. The rows of matrix M (where rows correspond to study participants and 650	
columns to HLA alleles or the IFNL4 genotypes) were randomly permuted 500 times 651	
and in each case the p-values of the associations were calculated. For each 652	
threshold t, the expected number of false significant associations was estimated by 653	
the mean number of false positives across permuted null data sets. The FDR for 654	
threshold t was then estimated as the mean number of false positives divided by the 655	
observed number of significant associations in the actual data at threshold t. 656	
 657	
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To test for enrichment of association signals in epitope regions, viral proteins or with 658	
a specific HLA allele we used Fisher’s exact test. Each site is either within a target 659	
region (epitope regions or a specific viral protein) or not and the most associated test 660	
with it, is significant or not with an FDR of 5%. The resulting contingency table was 661	
tested using Fisher’s exact test to assess enrichment or depletion of signals of 662	
association. 663	
 664	
To assess the relationship between rates of escape and reversion in HLA 665	
presentation, we estimated the odds ratio for each 2x2 sub-table used in the Fisher’s 666	
exact test. This was done only for viral sites associated with HLA alleles at 20% FDR 667	
and which there were sufficient observations in both tables to estimate the odds ratio 668	
where confidence interval did not go to infinity. Pearson’s correlation coefficient was 669	
used to assess the relationship between the log10(OR) of escape and reversion. 670	
 671	
To test for enrichment of viral amino acid associations with host IFNL4 genotypes in 672	
viral proteins, the null distribution of number of association in each protein was 673	
estimated using 10,000 permutations of IFNL4 labels and performing the same tests. 674	
The estimated null distribution of number of associations for each viral protein was 675	
compared to the observed number of associations in the data to test for enrichment 676	
or depletion of number of associations. To test if HVR1, HVR2, HVR3, ISDR and 677	
PKR-BD regions show differences in the number of changes away from the 678	
population consensus in CC and non-CC hosts, we used a Poisson regression. In 679	
each individual and each locus we determined the number of differences to the 680	
population consensus. We then estimated the effect of IFNL4 genotypes on the 681	
mean number of differences to the population consensus using Poisson regression. 682	
The same procedure was used to test if the total number of differences across the 683	
whole poly-protein relative to the population consensus was influenced by IFNL4 684	
genotypes. 685	
 686	
To estimate the rate of synonymous and non-synonymous mutations, we used 687	
dndsml function from MATLAB (Release 2015a, The MathWorks) that uses Goldman 688	
and Yang’s method. It estimates (using maximum likelihood) an explicit model for 689	
codon substitution that takes into account transition/transversion rate bias and 690	
base/codon frequency bias. Then it uses the model to correct synonymous and non-691	
synonymous counts to account for multiple substitutions at the same site. To 692	
estimate dN and dS, each sequence was compared to the population consensus 693	
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which indicates the most common nucleotide observed in our data set at each 694	
position along the genome. 695	
 696	
To determine whether IFNL4 genotypes impact on HLA alleles presentation of 697	
epitopes, logistic regression with interaction term was used. The outcome for 698	
individuals was whether on the terminal branches of the tree a specific had changed 699	
amino or not. We tested for interaction between presence and absence of the 700	
associated HLA allele and IFNL4 genotypes for all combinations of HLA alleles and 701	
viral sites associated at a 20% FDR. In addition, we tested for an overall effect of 702	
IFNL4 genotypes on HLA alleles’ presentation of epitopes. We used our 2x4 703	
contingency tables and the odds ratios estimated from the 2x2 sub-tables to infer the 704	
antigenic amino acids. If the odds ratio indicates that in individuals with HLA allele 705	
present, the "X ancestral amino acid -> any other amino acid" element is enriched 706	
relative to individuals without the HLA allele then we assume the X amino acid is the 707	
antigenic amino acid and escape occurs away from X to any other amino acid. For 708	
these cases, we count how many of "X ancestral amino acid -> any other amino acid" 709	
occur in CC and non-CC individuals across all combinations of HLA alleles and viral 710	
sites associated at 20% FDR. If IFNL4 genotypes have no impact on the HLA 711	
presentation (null hypothesis), then the mean number of escape mutations in CC and 712	
non-CC hosts should be proportional to the frequency of hosts with CC and non-CC 713	
genotypes (null distribution is binomial with parameters n equal to the total number of 714	
observed escape mutations and p equal to the proportion of CC hosts).  715	
 716	
We used linear regression in PLINK251 (https://www.cog-genomics.org/plink2) to test 717	
for association between human SNPs and log10 transformed pre-treatment  viral load 718	
(PTVL) including sex and first three PCs of the host genome as covariates. We used 719	
linear regression to test for association between HCV amino acids (with a minimal 720	
count of 10 at each site) and viral load. We used linear regression in R (version 3.2.4 721	
(2016-03-10))62 to analyse the interaction between IFNL4 genotypes and amino 722	
acids at viral site 2414 and to quantify their impact on viral load. 723	
 724	
For all viral sites associated with IFNL4 genotypes at 20% FDR, we assessed if there 725	
is a relationship between effect size of non-consensus amino acids on viral load and 726	
effect size of IFNL4 genotypes and changes to non-consensus amino acids. We 727	
estimated the odds ratio of enrichment of changes away from the consensus amino 728	
acid on the terminal branches of the virus tree in CC and non-CC genotypes (2x2 729	
contingency table, only using data in which the consensus is inferred to be 730	
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ancestral). We also estimated the effect size of non-consensus amino acids on the 731	
log10 of viral load using a linear regression with IFNL4 genotype as a covariate. 732	
Additionally, we estimated the effect size of non-consensus amino acid on the log10 733	
viral load in CC and non-CC hosts. We used Pearson’s correlation coefficient to 734	
measure the strength of relationship between the effect size of non-consensus amino 735	
acids on viral load and log of odds ratio of enrichment of non-consensus amino acid 736	
changes in CC hosts. 737	
Code Availability 738	
R and MATLAB code used to generate the results and figures from the primary 739	
analyses described above are available from the authors on request. 740	
Replication study 741	
To replicate the IFNL4 SNP rs12979860 results, we ran the association analysis on 742	
an independent HCV infected population	that was recruited to the FISSION, FUSION 743	
and POSITRON phase 3 clinical studies38,39. The Material Transfer Agreements 744	
under which the data were shared limited analysis to the NS5B protein. Paired 745	
human genome-wide genotyping and HCV sanger sequencing data for NS5B 746	
amplicon were obtained from DNA and plasma samples collected from 360 747	
Caucasian patients chronically infected with HCV genotype 2 (N=153) or 3 (N=208). 748	
We searched for association between the IFNL4 SNP rs12979860 and viral position 749	
2570 using logistic regression with the outcome indicated by the presence or 750	
absence of amino acid V at position 2570. To help prevent spurious associations due 751	
to host and viral stratification, we included human principal components and viral 752	
genotype as covariates.  753	
Replicon assay 754	
Cell Culture 755	
Huh7.5-Sec14L2 cells, previously reported40 were grown in Dulbecco’s modified 756	
Eagle’s medium (DMEM, Life Technologies) supplemented with 10% fetal calf 757	
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 0 enicillin, 100  100 lmM HEPES 758	
and 0.1M nonessential amino acids as described63. Huh7.5 cells are heterozygous 759	
CT for the IFNL4 rs12979860 SNP64. 760	
HCV Mutant Replicons 761	
The enhanced version of the subgenomic replicon of genotype 3a strain S52, lacking 762	
of neomycin resistance gene, has been previously described40. Site-specific 763	
mutations were introduced using QuikChange II XL Site-Directed Mutagenesis Kit 764	
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(Agilent Technologies) following manufacturer instructions and confirmed by direct 765	
sequencing. HCV mutant plasmids were linearized by XbaI digestion (New England 766	
Biolabs; NEB), mung-bean treated (NEB) and purified. Linearized DNA was then 767	
used as template for in vitro RNA transcription (IVT) (Megascript T7, Life 768	
Technologies) according to manufacturer protocol. Finally, IVT RNA has been 769	
DNAse treated, purified and stored at -80°C. 770	
Electroporation and Luciferase Detection 771	
For electroporation, cells were counted and then washed twice in ice-cold PBS. 772	
Typically, for each mutant 4x106 cells were mixed with 1 µg of replicon RNA in a 773	
4mm cuvette and electroporated in the Gene Pulser Xcell (Bio-Rad) at 250 V, 950 µF 774	
using exponential decay setting. Cells were immediately recovered in pre-warmed 775	
complete DMEM, seeded in a 24-well plate and incubated at 37°C. After 5, 24, 48 or 776	
72 hours, medium was removed and cells lysed with Glo Lysis Buffer (Promega). 777	
Cell lysates were then transferred in a white 96-well plate (Corning) and the 778	
luciferase expression was quantitated in a luminometer (GloMax 96 Microplate 779	
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Table 1. Associations between HLA alleles and viral amino acids at a 5% false 957	
discovery rate. In the whole cohort (All) or in HCV genotype 3a self-reported “White” 958	
patients only (G3a White). Significant associations are in bold. For each combination 959	
of HLA allele and viral site, only the most significant associated amino acid is 960	
reported. Amino acids are ordered by decreasing frequency in the column “variable 961	



















G3a White  
 q value 





B*07:02 42 C PL P 1.55x10-07 5.00x10-03 8.07x10-07 5.81x10-03 Yes 
C*07:02 42 C PL P 2.27x10-07 6.10x10-03 1.99x10-07 1.33x10-03 Yes 
B*41:02 109 C PQSAL S 4.29x10-06 8.09x10-02 9.84x10-06 4.93x10-02 No 
B*13:02 348 E1 ILVM I 8.13x10-06 1.04x10-01 1.25x10-06 8.78x10-03 No 
C*08:02 372 E1 ATVIFC I 7.33x10-04 4.12x10-01 9.41x10-06 4.93x10-02 No 
A*29:02 444 E2 YHFRVWL Y 1.85x10-04 2.89x10-01 4.02x10-06 2.39x10-02 No 
C*15:02 561 E2 VTLI L 5.70x10-07 1.50x10-02 6.80x10-04 5.92x10-01 No 
DRB1*14:04 905 NS2 ATSC S 4.45x10-03 5.19x10-01 5.58x10-07 4.20x10-03 No 
A*31:01 1270 NS3 RKHS R 1.95x10-09 4.44x10-04 6.20x10-08 3.64x10-04 Yes 
A*33:03 1282 NS3 NVTSA T 1.73x10-07 5.26x10-03 4.14x10-02 9.13x10-01 Yes 
B*15:01 1290 NS3 KPARS R 1.25x10-07 4.47x10-03 3.64x10-06 2.39x10-02 Yes 
A*68:02 1341 NS3 VA V 2.43x10-09 4.44x10-04 9.93x10-07 6.91x10-03 No 
A*68:02 1344 NS3 TVA T 3.68x10-10 <4.00x10-04 9.22x10-11 <2.50x10-04 No 
B*51:01 1380 NS3 ILV L 3.22x10-08 1.67x10-03 2.10x10-07 1.38x10-03 Yes 
A*01:01 1444 NS3 FY F 9.63x10-33 <4.00x10-04 7.18x10-24 <2.50x10-04 Yes 
A*68:02 1452 NS3 IV I 6.98x10-09 4.44x10-04 3.84x10-07 2.89x10-03 No 
A*30:02 1585 NS3 YF Y 1.19x10-06 3.28x10-02 6.89x10-05 1.90x10-01 No 
B*13:02 1635 NS3 ITVLAF T 7.38x10-08 3.13x10-03 1.65x10-07 1.00x10-03 No 
B*08:01 1646 NS3 MTAVSI T 2.89x10-12 <4.00x10-04 2.01x10-10 <2.50x10-04 No 
C*07:01 1646 NS3 MTAVSI T 3.01x10-07 7.39x10-03 1.40x10-08 <2.50x10-04 No 
DQA1*05:01 1646 NS3 MTAVSI T 7.24x10-07 1.76x10-02 1.18x10-05 5.64x10-02 No 
B*57:01 1759 NS4B AVTGNSDI A 3.38x10-05 1.83x10-01 4.01x10-06 2.39x10-02 No 
A*02:01 1873 NS4B LFKICVPRMTA F 4.06x10
-10 <4.00x10-04 2.58x10-08 2.50x10-04 No 
B*38:01 2034 NS5A STNLPIAQVDKEMGRFW P 7.56x10
-08 3.13x10-03 6.35x10-08 3.64x10-04 Yes 
C*12:03 2034 NS5A STLPQKVAIRMFW P 9.31x10
-06 1.05x10-01 3.99x10-06 2.39x10-02 Yes 
B*18:01 2144 NS5A ED E 1.16x10-06 3.28x10-02 2.36x10-06 1.67x10-02 Yes 
B*51:01 2148 NS5A MTVSLKIA V 2.77x10-06 6.07x10-02 4.60x10-07 3.16x10-03 Yes 
C*14:02 2148 NS5A MTVSLKIA V 1.91x10-05 1.34x10-01 2.32x10-06 1.67x10-02 Yes 
B*40:01 2248 NS5A TSKAN T 5.76x10-04 3.91x10-01 9.62x10-06 4.93x10-02 No 
DQA1*01:01 2486 NS5B TIANSV T 4.71x10-05 1.96x10-01 5.12x10-06 2.90x10-02 Yes 
A*31:01 2510 NS5B AKQSEMGLTV A 4.96x10
-08 2.14x10-03 1.79x10-06 1.35x10-02 No 
A*32:01 2537 NS5B NDHSYEAI N 1.13x10-08 7.27x10-04 4.77x10-06 2.75x10-02 Yes 
A*32:01 2540 NS5B RSKHNQC R 7.45x10-09 6.00x10-04 5.96x10-12 <2.50x10-04 Yes 
A*02:11 2600 NS5B QKRSAL Q 1.01x10-06 3.12x10-02 NA NA Yes 
	 31	
A*26:01 2605 NS5B EAGVK G 2.61x10-07 6.64x10-03 5.91x10-05 1.73x10-01 Yes 
B*51:01 2713 NS5B ILMV I 7.70x10-06 1.03x10-01 1.25x10-08 <2.50x10-04 No 
A*25:01 2821 NS5B RCQL R 8.31x10-06 1.04x10-01 2.51x10-06 1.73x10-02 No 
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 966	
